(Q38219481)

31 August 2017

Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus (English)

1 reference

31 August 2017

1 reference

Michael H Davidson

1

1 reference

PubMed ID

24918792

31 August 2017

language of work or name

English

0 references

publication date

1 May 2014

1 reference

31 August 2017

Postgraduate Medicine

1 reference

31 August 2017

126

1 reference

31 August 2017

3

1 reference

31 August 2017

56-65

1 reference

Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?

31 August 2017

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Individualizing targets and tactics for high-risk patients with type 2 diabetes: practical lessons from ACCORD and other cardiovascular trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Hyperglycemic switch from mitochondrial nitric oxide to superoxide production in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Hyperglycemia-induced activation of nuclear transcription factor kappaB in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Circulating endothelial progenitor cells and cardiovascular outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Myocardial glucose transport and utilization in patients with type 2 diabetes mellitus, left ventricular dysfunction, and coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Platelet dysfunction in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

The platelet in diabetes: focus on prevention of ischemic events

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensit

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Apolipoprotein CIII links dyslipidemia with atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Cardiovascular biology of the incretin system

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Inflammation in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Sitagliptin: anti-platelet effect in diabetes and healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2756

21 January 2018

Identifiers

DOI

10.3810/PGM.2014.05.2756

1 reference

31 August 2017

1 reference

PubMed ID

24918792